This physician exchange activity at a national conference includes a panel of junior faculty physicians in hematology/oncology and transplant discussing allogeneic stem cell transplant in the management of adult patients with high-risk myelodysplastic syndrome (MDS). They’ll cover research, tools and clinical trials considered, best practices and shared challenges when considering transplant for this patient.
This educational activity is derived from the physician exchange roundtable meeting at a national conference, originally held on September 4, 2024.
Speakers
Minoo Battiwalla, MD, MS
Director, Outcomes Research
Sarah Cannon Transplant and Cell Therapy Network
Nashville, TN, USA
Minoo Battiwalla, M.D., M.S. joined Sarah Cannon in 2018 as the director of outcomes research. In his role, he designs and leads retrospective outcomes research across the Sarah Cannon Blood Cancer Network with a special emphasis on blood and marrow stem cell transplantation and cellular therapy.
Dr. Battiwalla received his medical degree from Medical College in Calcutta, India in 1994. After completing an internal medicine residency at Stony Brook University Hospital, NY, he finished a fellowship in hematology/oncology/BMT at National Institutes of Health in Bethesda, MD. He also earned a Master of Health Science degree in clinical research in 2003 from Duke University School of Medicine.
Prior to joining Sarah Cannon, Dr. Battiwalla served as the medical director of the Blood and Marrow Stem Cell Transplant Program at the National Heart, Lung and Blood Institute, Bethesda, MD from 2010-2018 and chaired the NIH BMT Consortium. Previous to this, he was an assistant professor and associate scientific director at the Roswell Park Cancer Institute, Buffalo, NY from 2003-2009.
Dr. Battiwalla has spearheaded efforts in the field of stem cell transplant survivorship and has co-chaired the NIH Late Effects after BMT consensus initiative as well as the Center for International Blood and Marrow Transplantation Late Effects Working Committee.
Dr. Battiwalla is actively certified by the American Board of Internal Medicine with further certification in Hematology.
Taha Al-Juhaisi, MD
Assistant Professor of Medicine
Stem Cell Transplantation and Cellular Therapy Program
Department of Medicine – Section of Hematology and Medical Oncology
University of Oklahoma Health Sciences Center - Stephenson Cancer Center
Oklahoma City, OK, USA
Dr. Taha Al-Juhaishi is an attending physician and a clinical investigator at OU Stephenson Cancer Center and currently also serves as the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy program, and an associate member of the Cancer Therapeutic Research program at the only NCI-designated cancer center in the state of Oklahoma. In addition to taking care of transplant and cell therapy patients, he also serves as principal investigator for several clinical trials and the associate program director for the Hematology and Oncology fellowship at the University of Oklahoma Health Sciences Center. Dr. Al-Juhaishi completed his medical school training at Weill Cornell Medicine in Qatar followed by Internal Medicine residency and Hematology /Oncology fellowship training at VCU and VCU Massey Cancer Center in Virginia. He then completed additional fellowship training in Stem Cell Transplantation and Cellular therapies at UT MD Anderson Cancer Center in Texas.
Clark Alsfeld, MD
Attending Physician
Ochsner MD Anderson Cancer Center
Ochsner Health
New Orleans, LA, USA
Onyee Chan, MD
Assistant Member
Malignant Hematology, Moffitt Cancer Center
Assistant Professor
Oncologic Sciences, University of South Florida
Tampa, FL, USA
Manuel Espinoza Gutarra, MD
Assistant Professor
University of Alabama at Birmingham
Birmingham, AL, USA
Warren Fingrut, MD
Assistant Professor
Department of Stem Cell Transplantation and Cellular Therapy
University of Texas MD Anderson Cancer Center
Houston, TX, USA
Dr. Warren Fingrut is an Assistant Professor with the Department of Stem Cell Transplantation and Cellular Therapy at the University of Texas MD Anderson Cancer Center. His academic interest is in characterizing and mitigating disparities in care delivery impacting patients from vulnerable populations. Clinically, he cares for patients with hematologic malignancies including MDS who are bone marrow transplant candidates and recipients.
Accreditation and Disclosure Information
Target Audience
This activity is intended for fellows and early career physicians and any other clinicians who treat patients with myelodysplastic syndromes or specializing in hematology/oncology or bone and marrow transplantation.
Agenda
- Identify shared challenges in MDS treatment.
- Examine current research, tools and clinical trials.
- Explore best practices in MDS risk stratification, timing & eligibility for transplant.
Educational Objectives
After completing this activity, the participant should be better able to:
- Identify shared challenges in MDS treatment among hematology/oncology and transplant teams.
- Examine current research, tools and clinical trials considered in the treatment of MDS with transplant.
- Describe best practices in MDS risk stratification, timing and eligibility for transplant.
Jointly provided by:
Accreditation and Credit Statements
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute Inc, and NMDP. Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Support Statement
There is no commercial support associated with this activity.
Disclosure & Conflict of Interest Policy
Medical Learning Institute Inc and NMDP are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Moderator
Minoo Battiwalla, MD, MS
Sarah Cannon Transplant and Cell Therapy Network
Minoo Battiwalla, MD, MS has a financial interest/relationship or affiliation in the form of:
Stock Ownership: Apellis Pharmaceuticals
The following relationships have ended within the last 24 months:
Research Grant: Fate Therapeutics, Novartis
Planner/Presenter
Taha Al-Juhaisi, MD
University of Oklahoma Health Sciences Center
Stephenson Cancer Center
Taha Al-Juhaisi, MD, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planner/Presenter
Clark Alsfeld, MD
Ochsner MD Anderson Cancer Center
Clark Alsfeld, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Bristol Myers Squibb
Speaker’s Bureau: Incyte, Kite
The following relationships have ended within the last 24 months:
Speaker’s Bureau: CTI BioPharma (ended March 2023)
Planner/Presenter
Onyee Chan, MD
Moffitt Cancer Center
Onyee Chan, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Bristol Myers Squibb, Partnership for Health Analytic Research
Research funding: AbbVie, Jazz Pharmaceuticals
The following relationships have ended within the last 24 months:
Consultant/Advisor: Aptitude Health (ended February 2024)
Planner/Presenter
Manuel Espinoza Gutarra, MD
University of Alabama at Birmingham Hospital
Manuel Espinoza Gutarra, MD, has a financial interest/relationship or affiliation in the form of:
Research funding: Bristol Myers Squibb
Planner/Presenter
Warren Fingrut, MD
University of Texas MD Anderson Cancer Center
Warren Fingrut, MD, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, and NMDP, the joint provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
About This Activity
Medical Learning Institute Inc and NMDP are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.
Copyright © 2024 Medical Learning Institute Inc | All Rights Reserved